BridgeBio Pharma: Morgan Stanley raises target price to $91 from $88
BBIO•Morgan Stanley raised its target price for BridgeBio Pharma to $91 from $88.
Related News
X-energy: Morgan Stanley cuts target price to $30 from $34
XE•
Nasdaq futures dip as Nvidia tumult keeps investors on edge
QQQ•
Korea's National Pension Service stake in Shinhan Financial falls to 9.20% from 9.26%
SHG•
Jacobs-AECOM joint venture wins Irish Rail consultancy contract
J•
Cushman & Wakefield names Enrica Bellei to cross-border luxury international role
CWK•